← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Capricor, Inc.
Beverly Hills, CA
$10,844,696
Total funding
4
Grants
Funding over time
peak $4M · FY2009–16$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$8,503,504 · 3
DOD$2,341,192 · 1
By mechanism
R44$3,826,855 · 1
RC3$2,993,268 · 1
—$2,341,192 · 1
UT2$1,683,381 · 1
Investigators at Capricor, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Safety and Efficacy of Allogeneic Cardiosphere-derived Stem Cells After MI$2,993,268
RC3 · FY2010 · HL
DEVELOPING A MANUFACTURING PROCESS FOR THERAPEUTIC EXOSOMES$2,341,192
· FY2016 · Department of the Army
The Allogeneic Heart Stem Cell Trial in Hypoplastic Left Heart Syndrome Patients$1,683,381
UT2 · FY2016 · HL
Safety of Allogeneic Cardiosphere-Derived Cells for Acute Myocardial Infarction$999,912
R44 · FY2013 · HL
Safety of Allogeneic Cardiosphere-Derived Cells for Dilated Cardiomyopathy$998,765
R44 · FY2014 · HL
Safety of Allogeneic Cardiosphere-Derived Cells for Dilated Cardiomyopathy$880,760
R44 · FY2015 · HL
Characterization and Potency of Optimized Cardiosphere-derived Stem Cell Method$425,410
R44 · FY2012 · HL
Characterization and Potency of Optimized Cardiosphere-derived Stem Cell Method$397,217
R44 · FY2011 · HL
Characterization and Potency of Optimized Cardiosphere-derived Stem Cell Method$124,791
R44 · FY2009 · HL